XOMA Co. (NASDAQ:XOMA - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $25.91 and traded as high as $27.05. XOMA shares last traded at $26.00, with a volume of 40,936 shares.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $117.00 target price on shares of XOMA in a research report on Friday, September 20th. StockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a research report on Wednesday, August 14th.
View Our Latest Stock Report on XOMA
XOMA Stock Up 2.0 %
The firm's fifty day moving average is $27.38 and its two-hundred day moving average is $25.91. The firm has a market cap of $304.20 million, a price-to-earnings ratio of -6.63 and a beta of 0.93. The company has a debt-to-equity ratio of 1.15, a current ratio of 8.71 and a quick ratio of 8.71.
XOMA (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). XOMA had a negative net margin of 128.59% and a negative return on equity of 24.50%. The company had revenue of $11.09 million during the quarter, compared to the consensus estimate of $8.37 million. On average, sell-side analysts expect that XOMA Co. will post -1.42 EPS for the current fiscal year.
Institutional Trading of XOMA
A number of hedge funds and other institutional investors have recently modified their holdings of XOMA. BNP Paribas Financial Markets raised its position in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 1,266 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in XOMA during the first quarter valued at approximately $212,000. Rhumbline Advisers boosted its holdings in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock worth $230,000 after buying an additional 1,334 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock worth $1,484,000 after buying an additional 1,968 shares during the last quarter. Institutional investors own 95.92% of the company's stock.
XOMA Company Profile
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Featured Articles
Before you consider XOMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA wasn't on the list.
While XOMA currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
